Chiauranib Plus Weekly Paclitaxel in Patients with Platinum-refractory or Platinum-resistant Recurrent Ovarian Cancer

This study is testing a combination of chiauranib (a targeted therapy) and weekly paclitaxel (a chemotherapy drug) for women with ovarian cancer that has come back and is no longer responding to platinum-based chemotherapy. **You may be eligible if:** - You are a woman aged 18–70 with confirmed ovarian, fallopian tube, or peritoneal cancer - Your cancer is platinum-refractory (progressed during or shortly after platinum therapy) or platinum-resistant (progressed within 6 months of platinum treatment) - You have received no more than 1 prior treatment regimen for recurrent disease - Your cancer is measurable on imaging - Your blood counts and organ function are within acceptable ranges - Your overall health is good (ECOG 0 or 1) **You may NOT be eligible if:** - You have received more than 1 prior treatment for recurrent disease - Your blood counts are too low (severe anemia, low platelets, or low neutrophils) - Your kidney or liver function is significantly impaired - Your cancer has not progressed on imaging during the last treatment Talk to your doctor to see if this trial is right for you.